Progress in Neurotherapeutics and Neuropsychopharmacology最新文献_第2页

Olanzapine as Maintenance Therapy in Patients with Bipolar I Disorder 奥氮平作为双相I型障碍患者的维持治疗

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2007-03-01 DOI: 10.1017/S1748232106000164

M. Tohen, D. Lin

{"title":"Olanzapine as Maintenance Therapy in Patients with Bipolar I Disorder","authors":"M. Tohen, D. Lin","doi":"10.1017/S1748232106000164","DOIUrl":"https://doi.org/10.1017/S1748232106000164","url":null,"abstract":"ABSTRACT Effective treatments for the prevention of relapse and recurrence of mood episodes in patients with bipolar disorder are essential to reduce the high mortality associated with this condition, and to improve long-term outcomes. While lithium is considered to be effective as a first line maintenance treatment, additional treatment options would provide clinicians with tools to address the needs of individual patients. The efficacy of olanzapine, an atypical antipsychotic, for the prevention of relapse in bipolar disorder has been demonstrated in several randomized controlled double-blind clinical trials, both as monotherapy and in combination with other agents. The data reviewed herein suggest a more robust efficacy of treatment with olanzapine in the prevention of relapse into manic episodes than into depressive episodes. The adverse events observed most frequently in patients treated with olanzapine relative to comparators were related to somnolence (somnolence, fatigue, or hypersomnia) and weight gain (weight gain, or increased appetite). Moreover, a larger proportion of olanzapine-treated patients than comparator-treated patients experienced clinically important weight gain.","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"114 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124380854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Pilot Clinical Trial of NT-3 in CMT1A Patients NT-3在CMT1A患者中的临床试验

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2007-03-01 DOI: 10.1017/S1748232106000073

Z. Sahenk

引用次数: 6

Comparative Neuropsychological Effects of Lamotrigine and Topiramate in Healthy Volunteers 拉莫三嗪和托吡酯对健康志愿者神经心理的比较作用

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2007-03-01 DOI: 10.1017/S1748232106000061

K. Meador

引用次数: 0

The NIMH MATRICS Initiative: Development of a Consensus Cognitive Battery NIMH矩阵倡议:共识认知电池的发展

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2007-03-01 DOI: 10.1017/S1748232106000127

R. Kern, Michael F. Green, S. Marder

引用次数: 6

The Phase II Futility Clinical Trial Design II期临床试验设计

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2007-03-01 DOI: 10.1017/S1748232106000048

B. Ravina, Y. Palesch

引用次数: 5

New Directions in Pediatric Neuro-Oncology Practice: Impact of the Children's Cancer Group Study 9933, a Phase II Study of High-Dose Chemotherapy Before Radiation in Children with Newly Diagnosed High-Grade Astrocytoma 儿童神经肿瘤学实践的新方向:儿童癌症组研究9933的影响，一项新诊断的高级别星形细胞瘤儿童放疗前大剂量化疗的II期研究

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2007-03-01 DOI: 10.1017/S1748232106000085

T. MacDonald

{"title":"New Directions in Pediatric Neuro-Oncology Practice: Impact of the Children's Cancer Group Study 9933, a Phase II Study of High-Dose Chemotherapy Before Radiation in Children with Newly Diagnosed High-Grade Astrocytoma","authors":"T. MacDonald","doi":"10.1017/S1748232106000085","DOIUrl":"https://doi.org/10.1017/S1748232106000085","url":null,"abstract":"ABSTRACT Background: Despite the use of surgery, radiotherapy (RT) and standard chemotherapy, childhood high-grade astrocytoma (HGA) continues to carry a dismal prognosis. In an attempt to identify effective drug combinations and an alternative treatment strategy, the Children's Cancer Group (CCG) conducted a nationwide clinical trial that prospectively evaluated 102 children with HGA and post-operative residual disease for efficacy and toxicity of four courses of high-dose chemotherapy (HDCT) before RT. Design and methods: Patients were randomly assigned to one of three couplets of drugs: carboplatin/etoposide (Regimen A); ifosfamide/etoposide (Regimen B); or cyclophosphamide/etoposide (Regimen C). After HDCT, all patients received local RT followed by lomustine and vincristine. Results: Of 76 evaluable patients (median age 11.95 years, range 3–20 years), 30 patients relapsed during HDCT and 11 others did not complete HDCT due to toxicity. Non-hematologic serious toxicities were common (29%) and 21% of patients did not receive RT. Objective response rates were not associated with amount of residual disease and did not statistically differ between regimens: 27% (Regimen A), 8% (Regimen B), and 29% (Regimen C). Overall survival (OS) was 24 ± 5% at 5 years and did not differ between groups. The 5-year, event-free survival (EFS) for all patients was 8 ± 3% and 14 ± 7% for Regimen A ( p = 0.07). Patients who responded to HDCT had a nominally higher survival rate ( p = 0.03 for trend). Interpretation: HDCT prior to RT provides no additional clinical benefit to conventional treatment in HGA, regardless of the amount of measurable residual tumor, and adversely effects ability to complete RT. Strong consideration should be given to investigating alternative strategies and novel biologic agents for this disease.","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127800415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treating Migraine Attacks ASAP: Concept and Methodological Issues 尽快治疗偏头痛:概念和方法问题

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2006-02-15 DOI: 10.1017/S1748232105000066

N. Wiendels, M. Ferrari

引用次数: 0

Selegiline in the Treatment of Negative Symptoms of Schizophrenia 斯来吉兰治疗精神分裂症阴性症状的疗效观察

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2006-02-15 DOI: 10.1017/S1748232105000121

Allison Lin, J. Bodkin

引用次数: 0

Liquid Fluoxetine versus Placebo for Repetitive Behaviors in Childhood Autism 液体氟西汀与安慰剂对儿童自闭症重复行为的影响

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 1900-01-01 DOI: 10.1017/S1748232105000108

E. Hollander, E. Swanson, E. Anagnostou, Ann T. Phillips, W. Chaplin, S. Wasserman

引用次数: 3

Introduction to Neurotherapeutics and Neuropsychopharmacology 神经治疗学和神经精神药理学导论

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 1900-01-01 DOI: 10.1017/S1748232105000029

J. Cummings

{"title":"Introduction to Neurotherapeutics and Neuropsychopharmacology","authors":"J. Cummings","doi":"10.1017/S1748232105000029","DOIUrl":"https://doi.org/10.1017/S1748232105000029","url":null,"abstract":"In recent years there has been tremendous progress in advancing new treatments for neurologic and psychiatric illnesses. New agents have emerged for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, migraine, schizophrenia, bipolar illness, depression, and substance abuse disorders. Advances in understanding of basic pathophysiology and molecular biology of brain disorders have led to increasingly sophisticated target identification that guides drug development. Advances in the basic neuroscience and disease mechanisms have been particularly obvious in the neurologic disorders where there is an ever improving understanding of the underlying mechanisms of brain function and brain disease. Progress in neurotherapeutics has occurred in concert with progress in basic science methodologies, neuroimaging, clinical trial design, and trial analysis. There is an increasing enthusiasm for clinical trials that provide highly credible data with which to guide evidence-based medicine. The United States Food and Drug Administration (US FDA) requires a close link between the clinical trial population tested and the specific indication for which the agent will be approved. This contributes to the proliferation of clinical trials, as industry sponsors of trials seek to expand the populations for which their products are indicated. An increasing number of patients and physicians are involved in clinical trials. Advancing clinical trial methodology has itself become a major endeavor.","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129834663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0